Extra-appendicular neuroendocrine tumors: A report from the TREP project (2000-2020).
carcinoid tumors
children
extra-appendicular neuroendocrine tumors
neuroendocrine tumors
rare cancer
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
08
10
2020
revised:
15
12
2020
accepted:
16
12
2020
pubmed:
2
2
2021
medline:
4
8
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
Extra-appendicular neuroendocrine tumors (NETs) are very rare tumors. While diagnostic and therapeutic guidelines are well established for adults, data on children and adolescents are lacking. Patients with a diagnosis of extra-appendicular NET registered on the Tumori Rari in Età Pediatrica - Rare Tumors in Pediatric Age (TREP) from 2000 to 2020 were analyzed. Clinical characteristics including patients' presentation, tumor features, treatment, and outcome were reviewed. Twenty-seven patients with extra-appendicular NET registered on TREP with a median age of 173 months. The primary site was the pancreas (12) or bronchi (10) in the majority of cases. Other primary sites included the thymus, Meckel's diverticulum, and liver. Thirteen (48%) of tumors extended beyond the organ of origin: four invaded neighboring organs and/or regional nodes and nine involved distant metastases. The 3-year event-free survival (EFS) for those with localized disease was superior to those with metastatic disease (66.6% 95% CI 5-95% vs 33% 95% CI 5-68%, respectively; P = .005). A complete resection was feasible in 17 patients. The 3-year EFS in these patients was superior to those with no or incomplete resection (R0 vs R1/R2, respectively; P = .007). Overall, 16 children had no evidence of disease at follow-up, and one is alive with disease; five died, and five were lost to follow-up. Data from our experience demonstrated a wide heterogeneity of presentation and outcome of these tumors. Localized disease and complete surgical resection were the main prognostic factors of good outcome. Other therapies may have a role in prolonging survival in metastatic disease.
Sections du résumé
BACKGROUND
Extra-appendicular neuroendocrine tumors (NETs) are very rare tumors. While diagnostic and therapeutic guidelines are well established for adults, data on children and adolescents are lacking.
PATIENTS AND METHODS
Patients with a diagnosis of extra-appendicular NET registered on the Tumori Rari in Età Pediatrica - Rare Tumors in Pediatric Age (TREP) from 2000 to 2020 were analyzed. Clinical characteristics including patients' presentation, tumor features, treatment, and outcome were reviewed.
RESULTS
Twenty-seven patients with extra-appendicular NET registered on TREP with a median age of 173 months. The primary site was the pancreas (12) or bronchi (10) in the majority of cases. Other primary sites included the thymus, Meckel's diverticulum, and liver. Thirteen (48%) of tumors extended beyond the organ of origin: four invaded neighboring organs and/or regional nodes and nine involved distant metastases. The 3-year event-free survival (EFS) for those with localized disease was superior to those with metastatic disease (66.6% 95% CI 5-95% vs 33% 95% CI 5-68%, respectively; P = .005). A complete resection was feasible in 17 patients. The 3-year EFS in these patients was superior to those with no or incomplete resection (R0 vs R1/R2, respectively; P = .007). Overall, 16 children had no evidence of disease at follow-up, and one is alive with disease; five died, and five were lost to follow-up.
CONCLUSIONS
Data from our experience demonstrated a wide heterogeneity of presentation and outcome of these tumors. Localized disease and complete surgical resection were the main prognostic factors of good outcome. Other therapies may have a role in prolonging survival in metastatic disease.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28880Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors. Cancer. 2003;97(4):934-959.
Cavalcoli F, Garrahy A, Castellaneta M, Tamagno G. Epidemiology of neuroendocrine tumours: by site of tumour and by geographical area. In: Neuroendocrine Tumors in Real Life. Berlin: Springer International Publishing; 2018:5-7.
Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer. 2011;56(1):50-57.
Sacco Casamassima MG, Gause CD, Goldstein SD, et al. Pancreatic surgery for tumors in children and adolescents. Pediatr Surg Int. 2016;32(8):779-788.
Stawarski A, Maleika P. Neuroendocrine tumors of the gastrointestinal tract and pancreas: is it also a challenge for pediatricians? Adv Clin Exp Med. 2020;29(2):265-270.
Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis, and related syndromes. Best Pract Res Clin Endocrinol Metab. 2010;24(3):439-449.
Mylonas KS, Nasioudis D, Tsilimigras DI, Doulamis IP, Masiakos PT, Kelleher CM. A population-based analysis of a rare oncologic entity: malignant pancreatic tumors in children. J Pediatr Surg. 2018;53(4):647-652.
De Caro MLDB, Guadagno E, De Rosa G. Pathological Classification: GEP, TNET, and Rare Forms. In: Neuroendocrine Tumors in Real Life. Berlin: Springer International Publishing; 2018:29-49.
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557-577.
Pavel M, O'Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172-185.
Öberg K, Hellman P, Ferolla P, Papotti M, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii120-vii123.
Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295-309.
Johnson PR. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children. Semin Pediatr Surg. 2014;23(2):91-95.
Redlich A, Wechsung K, Boxberger N, Leuschner I, Vorwerk P. Extra-appendiceal neuroendocrine neoplasms in children - data from the GPOH-MET 97 Study. Klin Padiatr. 2013;225(6):315-319.
Mylonas KS, Doulamis IP, Tsilimigras DI, et al. Solid pseudopapillary and malignant pancreatic tumors in childhood: a systematic review and evidence quality assessment. Pediatr Blood Cancer. 2018;65(10):e27114.
Njere I, Smith LL, Thurairasa D, et al. Systematic review and meta-analysis of appendiceal carcinoid tumors in children. Pediatr Blood Cancer. 2018;65(8):e27069.
de Lambert G, Lardy H, Martelli H, Orbach D, Gauthier F, Guérin F. Surgical management of neuroendocrine tumors of the appendix in children and adolescents: a retrospective French multicenter study of 114 cases. Pediatr Blood Cancer. 2016;63(4):598-603.
Virgone C, Cecchetto G, Alaggio R, et al. Appendiceal neuroendocrine tumours in childhood: Italian TREP project. J Pediatr Gastroenterol Nutr. 2014;58(3):333-338.
Broaddus RR, Herzog CE, Hicks MJ. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med. 2003;127(9):1200-1203.
Spunt SL, Pratt CB, Rao BN, et al. Childhood carcinoid tumors: the St Jude Children's Research Hospital experience. J Pediatr Surg. 2000;35:1282-1286.
Ferrari A, Bisogno G, De Salvo GL, et al. The challenge of very rare tumors in childhood: the Italian TREP project. Eur J Cancer. 2007;43:654.
Réguerre Y, Lacour B, André N, et al. Epidemiology and management of rare paediatric tumours within the framework of the French Society for Children Cancer. Bull Cancer. 2010;97(9):1041-1045.
Schneider DT, Brecht IB. Care for rare cancers: improved care requires improved communication. Klin Padiatr. 2010;222(3):124-126.
Brecht IB, Graf N, Schweinitz D, Frühwald MC, Bielack SS, Schneider DT. Networking for children and adolescents with very rare tumors: foundation of the GPOH Pediatric Rare Tumor Group. Klin Padiatr. 2009;221(3):181-185.
Balcerska A, Godzinski J, Bien E, et al. [Rare tumours - are they really rare in the Polish children population?] Przegl Lek. 2004;61(Suppl 2):57-61.
Pastore G, De Salvo GL, Bisogno G, et al. Evaluating access to pediatric cancer care centers of children and adolescents with rare tumors in Italy: the TREP project. Pediatr Blood Cancer. 2009;53:152.
Degnan AJ, Tocchio S, Kurtom W, Tadros SS. Pediatric neuroendocrine carcinoid tumors: management, pathology, and imaging findings in a pediatric referral center. Pediatr Blood Cancer. 2017;64(9):e26477.
Pio L, Varela P, Eliott MJ, et al. Pediatric airway tumors: a report from the International Network of Pediatric Airway Teams (INPAT). Laryngoscope. 2020;130(4):E243-E251.
Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707-714.
Virgone C, Andreetta M, Avanzini S, et al. Pheochromocytomas and paragangliomas in children: data from the Italian Cooperative Study (TREP). Pediatr Blood Cancer. 2020;67(8):e28332.
Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24(9):R315-R334.
O'Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumours? Rev Endocr Metab Disord. 2017;18(4):499-515.
Reuling EMBP, Dickhoff C, Plaisier PW, Bonjer HJ, Daniels JMA. Endobronchial and surgical treatment of pulmonary carcinoid tumors: a systematic literature review. Lung Cancer. 2019;134:85-95.
Al-Qahtani AR, Di Lorenzo M, Yazbeck S. Endobronchial tumors in children: institutional experience and literature review. J Pediatr Surg. 2003;38(5):733-736.
Roby BB, Drehner D, Sidman JD. Pediatric tracheal and endobronchial tumors: an institutional experience. Arch Otolaryngol Head Neck Surg. 2011;137(9):925-929.
Fauroux B, Aynie V, Larroquet M, et al. Carcinoid and mucoepidermoid bronchial tumours in children. Eur J Pediatr. 2005;164(12):748-752.
Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784-798.
Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26(8):1604-1620.
Howell DL, O'Dorisio MS. Management of neuroendocrine tumors in children, adolescents, and young adults. J Pediatr Hematol Oncol. 2012;34(Suppl 2):S64-S68.
Gómez FM, Patel PA, Stuart S, Roebuck DJ. Systematic review of ablation techniques for the treatment of malignant or aggressive benign lesions in children. Pediatr Radiol. 2014;44(10):1281-1289.
Zambaiti E, Siles Hinojosa A, Montano V, et al. Interventional radiology-guided procedures in the treatment of pediatric solid tumors: a systematic review and meta-analysis from the group of young pediatric surgeons of Europe. Eur J Pediatr Surg. 2019;30(4):317-325.
Lobe TE, Vera SR, Bowman LC, Fontanesi J, Britt LG, Gaber AO. Hepaticopancreaticogastroduodenectomy with transplantation for metastatic islet cell carcinoma in childhood. J Pediatr Surg. 1992;27:227-229.
Ferrari A, Schneider DT, Bisogno G, EXPeRT Board. The founding of the European Cooperative Study Group on Pediatric Rare Tumors-EXPeRT. Expert Rev Anticancer Ther. 2013;13(1):1-3.
Pappo AS, Furman WL, Schultz KA, Ferrari A, Helman L, Krailo MD. Rare tumors in children: progress through collaboration. J Clin Oncol. 2015;33(27):3047-3054.
Indini A, Bisogno G, Cecchetto G, et al. Gastrointestinal tract carcinoma in pediatric and adolescent age: the Italian TREP project experience. Pediatr Blood Cancer. 2017;64(12):e26658.
Ferrari A, Casanova M, Massimino M, Sultan I. Peculiar features and tailored management of adult cancers occurring in pediatric age. Expert Rev Anticancer Ther. 2010;10(11):1837-1851.